Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Increased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 242,007 shares of the life sciences company’s stock after purchasing an additional 27,190 shares during the period. Stephens Investment Management Group LLC’s holdings in Illumina were worth $32,339,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Cetera Investment Advisers grew its holdings in shares of Illumina by 25.8% during the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock valued at $1,919,000 after acquiring an additional 3,767 shares in the last quarter. Diversified Trust Co purchased a new position in Illumina in the third quarter valued at about $243,000. CWM LLC increased its position in Illumina by 179.8% in the 3rd quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock worth $2,114,000 after purchasing an additional 10,414 shares during the last quarter. Perpetual Ltd purchased a new stake in shares of Illumina during the 3rd quarter worth about $723,000. Finally, UMB Bank n.a. lifted its holdings in shares of Illumina by 23.7% during the 3rd quarter. UMB Bank n.a. now owns 1,659 shares of the life sciences company’s stock valued at $216,000 after buying an additional 318 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 9.6 %

Illumina stock opened at $111.06 on Friday. The business has a 50 day moving average price of $136.70 and a two-hundred day moving average price of $135.29. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Equities research analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Royal Bank of Canada cut their price objective on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. Leerink Partners increased their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and reduced their price target for the stock from $177.00 to $140.00 in a research report on Friday. Finally, Piper Sandler lowered their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Nine investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $161.40.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.